




RealRate

PHARMACEUTICAL 2020

Diamedica Therapeutics Inc
Rank 188 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Diamedica Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Diamedica Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Diamedica Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is 241%, being 2.8% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	8,836
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,318
Liabilities, Non-Current	118
Other Assets	153
Other Compr. Net Income	2.0
Other Expenses	31
Other Liabilities	0
Other Net Income	975
Other Revenues	0
Property and Equipment	64
Research and Development	7,900
Selling, General and Administrative Expense	3,693

Output Variable	Value in 1000 USD
Assets	9,053
Liabilities	1,436
Expenses	11,624
Revenues	0
Stockholders Equity	7,617
Net Income	-10,649
Comprehensive Net Income	-10,648
BaseVar	11,545
ECR before Limited Liability	114%
Economic Capital Ratio	241%